GPP
IOVA icon

Great Point Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Great Point Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200,000
Closed -$3.64M – 42
2019
Q3 		$3.64M Hold
200,000
– – 0.33% 37
2019
Q2 		$4.9M Buy
+200,000
New +$3.01M 0.54% 24

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Great Point Partners's IOVA Position: Q2 2021 in Review

Great Point Partners sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 930,000 shares — an estimated $29.4M sold.

Great Point Partners first reported a position in IOVA in Q2 2017 and held it in 16 quarters. The position peaked at $139M in Q4 2019. 233 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Great Point Partners reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Great Point Partners sold 930,000 Iovance Biotherapeutics shares in Q2 2021, an estimated $29.4M.
  • Great Point Partners first reported a position in Iovance Biotherapeutics in Q2 2017 and held it in 16 quarters.
  • Great Point Partners's Iovance Biotherapeutics position peaked at $139M in Q4 2019.
  • 233 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Great Point Partners's 13F filing for Q2 2021, filed 16 Aug 2021.